Vaxcyte (NASDAQ:PCVX) EVP Sells $79,399.68 in Stock

Vaxcyte, Inc. (NASDAQ:PCVX) EVP Jim Wassil sold 1,334 shares of the stock in a transaction that occurred on Wednesday, September 9th. The shares were sold at an average price of $59.52, for a total transaction of $79,399.68. Following the completion of the sale, the executive vice president directly owned 145,435 shares in the company, valued at approximately $8,656,291.20. This represents a 0.91% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jim Wassil also recently made the following trade(s):

• On Friday, September 4th, Jim Wassil sold 1,381 shares of Vaxcyte stock. The stock was sold at an average price of $61.16, for a total transaction of $84,461.96.
• On Tuesday, September 1st, Jim Wassil sold 3,477 shares of Vaxcyte stock. The shares were sold at an average price of $61.07, for a total value of $212,340.39.
• On Monday, August 3rd, Jim Wassil sold 2,250 shares of Vaxcyte stock. The shares were sold at an average price of $53.86, for a total value of $121,185.00.
• On Wednesday, July 1st, Jim Wassil sold 2,250 shares of Vaxcyte stock. The shares were sold at an average price of $56.33, for a total value of $126,742.50.

Vaxcyte Price Performance

Shares of NASDAQ PCVX opened at $59.47 on Friday. The business has a 50-day moving average of $58.44 and a two-hundred day moving average of $56.34. The company has a market capitalization of $8.85 billion, a price-to-earnings ratio of -7.79 and a beta of 1.22. Vaxcyte, Inc. has a 1 year low of $30.81 and a 1 year high of $65.00.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($1.97) EPS for the quarter, beating analysts’ consensus estimates of ($2.06) by $0.09. During the same period in the previous year, the company posted ($1.22) earnings per share. As a group, equities research analysts expect that Vaxcyte, Inc. will post -7.6 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have weighed in on PCVX. Wall Street Zen raised shares of Vaxcyte from a “strong sell” rating to a “sell” rating in a report on Saturday, August 8th. Zacks Research raised shares of Vaxcyte from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 12th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Vaxcyte in a research note on Monday, July 6th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $98.00.

Institutional Trading of Vaxcyte

A number of large investors have recently made changes to their positions in PCVX. Smartleaf Asset Management LLC grew its stake in Vaxcyte by 156.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 597 shares of the company’s stock worth $27,000 after buying an additional 364 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its stake in Vaxcyte by 1,463.4% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 641 shares of the company’s stock valued at $30,000 after buying an additional 600 shares during the last quarter. IFP Advisors Inc lifted its stake in Vaxcyte by 72.8% in the second quarter. IFP Advisors Inc now owns 560 shares of the company’s stock valued at $33,000 after buying an additional 236 shares during the last quarter. EverSource Wealth Advisors LLC boosted its holdings in shares of Vaxcyte by 33.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company’s stock valued at $34,000 after acquiring an additional 184 shares during the period. Finally, CIBC Private Wealth Group LLC boosted its holdings in shares of Vaxcyte by 22,500.0% in the third quarter. CIBC Private Wealth Group LLC now owns 1,356 shares of the company’s stock valued at $49,000 after acquiring an additional 1,350 shares during the period. 96.78% of the stock is owned by institutional investors and hedge funds.

Vaxcyte Company Profile

Vaxcyte, Inc is a clinical-stage biotechnology company focused on developing vaccines to prevent serious bacterial infections. The company’s lead programs target pneumococcal disease, which can cause pneumonia, meningitis, bloodstream infections and other invasive illnesses. Vaxcyte is developing broad-spectrum pneumococcal conjugate vaccine candidates designed to protect against a wide range of bacterial serotypes.

Vaxcyte’s pipeline has included VAX-24, an investigational 24-valent pneumococcal conjugate vaccine, and VAX-31, a next-generation candidate designed to cover 31 serotypes.